Literature DB >> 29437874

Comparison of Species and Cell-Type Differences in Fraction Unbound of Liver Tissues, Hepatocytes, and Cell Lines.

Keith Riccardi1, Sangwoo Ryu1, Jian Lin1, Phillip Yates1, David Tess1, Rui Li1, Dhirender Singh1, Brian R Holder1, Brendon Kapinos1, George Chang1, Li Di2.   

Abstract

Fraction unbound (fu) of liver tissue, hepatocytes, and other cell types is an essential parameter used to estimate unbound liver drug concentration and intracellular free drug concentration. fu,liver and fu,cell are frequently measured in multiple species and cell types in drug discovery and development for various applications. A comparison study of 12 matrices for fu,liver and fu,cell of hepatocytes in five different species (mouse, rat, dog, monkey, and human), as well as fu,cell of Huh7 and human embryonic kidney 293 cell lines, was conducted for 22 structurally diverse compounds with the equilibrium dialysis method. Using an average bioequivalence approach, our results show that the average difference in binding to liver tissue, hepatocytes, or different cell types was within 2-fold of that of the rat fu,liver Therefore, we recommend using rat fu,liver as a surrogate for liver binding in other species and cell types in drug discovery. This strategy offers the potential to simplify binding studies and reduce cost, thereby enabling a more effective and practical determination of fu for liver tissues, hepatocytes, and other cell types. In addition, fu under hepatocyte stability incubation conditions should not be confused with fu,cell, as one is a diluted fu and the other is an undiluted fu Cell density also plays a critical role in the accurate measurement of fu,cell.
Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29437874     DOI: 10.1124/dmd.117.079152

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  6 in total

1.  Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches.

Authors:  Yingying Guo; Xiaoyan Chu; Neil J Parrott; Kim L R Brouwer; Vicky Hsu; Swati Nagar; Pär Matsson; Pradeep Sharma; Jan Snoeys; Yuichi Sugiyama; Daniel Tatosian; Jashvant D Unadkat; Shiew-Mei Huang; Aleksandra Galetin
Journal:  Clin Pharmacol Ther       Date:  2018-09-12       Impact factor: 6.875

2.  Novel Bile Acid-Dependent Mechanisms of Hepatotoxicity Associated with Tyrosine Kinase Inhibitors.

Authors:  Chitra Saran; Louise Sundqvist; Henry Ho; Jonna Niskanen; Paavo Honkakoski; Kim L R Brouwer
Journal:  J Pharmacol Exp Ther       Date:  2021-11-18       Impact factor: 4.402

3.  Albumin-Mediated Uptake Improves Human Clearance Prediction for Hepatic Uptake Transporter Substrates Aiding a Mechanistic In Vitro-In Vivo Extrapolation (IVIVE) Strategy in Discovery Research.

Authors:  Na Li; Akshay Badrinarayanan; Kazuya Ishida; Xingwen Li; John Roberts; Shuai Wang; Mike Hayashi; Anshul Gupta
Journal:  AAPS J       Date:  2020-11-16       Impact factor: 4.009

4.  Recent developments in in vitro and in vivo models for improved translation of preclinical pharmacokinetics and pharmacodynamics data.

Authors:  Jaydeep Yadav; Mehdi El Hassani; Jasleen Sodhi; Volker M Lauschke; Jessica H Hartman; Laura E Russell
Journal:  Drug Metab Rev       Date:  2021-05-25       Impact factor: 6.984

5.  Impact of Intracellular Concentrations on Metabolic Drug-Drug Interaction Studies.

Authors:  Andrea Treyer; Mohammed Ullah; Neil Parrott; Birgit Molitor; Stephen Fowler; Per Artursson
Journal:  AAPS J       Date:  2019-06-18       Impact factor: 4.009

6.  A Cell-Free Approach Based on Phospholipid Characterization for Determination of the Cell Specific Unbound Drug Fraction (fu,cell).

Authors:  Andrea Treyer; Sandra Walday; Hinnerk Boriss; Pär Matsson; Per Artursson
Journal:  Pharm Res       Date:  2019-11-07       Impact factor: 4.200

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.